Truist Financial Corp Sells 36,611 Shares of Sanofi (NASDAQ:SNY)

Truist Financial Corp cut its holdings in Sanofi (NASDAQ:SNY) by 6.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 560,623 shares of the company’s stock after selling 36,611 shares during the period. Truist Financial Corp’s holdings in Sanofi were worth $27,039,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Northwest Investment Counselors LLC bought a new position in shares of Sanofi in the third quarter valued at approximately $29,000. Synergy Asset Management LLC bought a new position in Sanofi during the fourth quarter valued at $25,000. Concord Wealth Partners grew its holdings in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the period. McClarren Financial Advisors Inc. grew its holdings in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Finally, Sunbelt Securities Inc. grew its holdings in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the period. 14.04% of the stock is owned by institutional investors.

Sanofi Price Performance

Sanofi stock opened at $53.95 on Wednesday. Sanofi has a one year low of $45.22 and a one year high of $58.97. The business has a fifty day moving average price of $50.54 and a 200-day moving average price of $52.48. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. The firm has a market capitalization of $136.92 billion, a P/E ratio of 21.67, a PEG ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi currently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.